COVID-19 highlighted vulnerabilities in medical manufacturing supply chain: Fitch

"We believe that over the longer term, govt may aim to source more key pharmaceutical ingredients locally as opposed to the current heavy reliance on China, and to a lesser degree India," it said. This provides an opportunity for the Indian govt to escalate domestic production of pharma ingredients to counteract an over-reliance on Chinese imports now hampered by COVID-19 shutdowns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3aqQcap
via IFTTT